Last reviewed · How we verify
Somatuline Depot (LANREOTIDE)
Somatuline Depot works by mimicking the natural hormone somatostatin to block the production of excess growth hormone.
Lanreotide (Somatuline Depot), marketed by Ipsen Pharma, is a leading somatostatin analog indicated for the treatment of acromegaly, competing in a class with drugs like octreotide and pasireotide. Its key strength lies in its mechanism of action, which effectively mimics natural somatostatin to block excess growth hormone production, positioning it as a robust therapeutic option. The primary risk to Lanreotide is the upcoming key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | LANREOTIDE |
|---|---|
| Sponsor | Ipsen Pharma |
| Drug class | Somatostatin Analog |
| Target | Somatostatin receptor type 2 |
| Modality | Recombinant protein |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 2007 |
| Annual revenue | 1200 |
Mechanism of action
Lanreotide, the active component of SOMATULINE DEPOT is an octapeptide analog of natural somatostatin. The mechanism of action of lanreotide is believed to be similar to that of natural somatostatin.
Approved indications
- Acromegaly
- GEP-NETs
- Carcinoid Syndrome
Common side effects
- Diarrhea
- Abdominal pain
- Injection site reactions
- Cholelithiasis
- Gastrointestinal disorders
- Flatulence
- Application Site Disorders
- Injection site mass/pain/reaction/inflammation
- Liver and Biliary System Disorders
- Bradycardia
- Red Blood Cell Disorders
- Anemia
Drug interactions
- Cyclosporine
- Bromocriptine
- Bradycardia-Inducing Drugs (e.g., beta-blockers)
- Insulin and Oral Hypoglycemic Drugs
- Drugs Metabolized by Cytochrome P450 Enzymes (e.g., quinidine, terfenadine)
Key clinical trials
- Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome (PHASE2)
- Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen (PHASE3)
- LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) (PHASE2)
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (PHASE3)
- Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula (PHASE3)
- A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (PHASE1)
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (PHASE3)
- Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Somatuline Depot CI brief — competitive landscape report
- Somatuline Depot updates RSS · CI watch RSS
- Ipsen Pharma portfolio CI